Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 158968 in Healthy Subjects
NCT05682352Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LEO 158968 (2 arms), sponsored by LEO Pharma. Primary endpoint: Number of Treatment-emergent Adverse Events. Started Feb 2023; status: completed.
02
Drugs
LEO 158968
Beyond the preview
Go deeper on NCT05682352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682352.